跳至主要内容
临床试验/NL-OMON51589
NL-OMON51589已完成不适用

Change in markers of immune function associated with Bacillus subtilis CU1 intervention in different age groups - BSCU1 and immune function

Gnosis by Lesaffre0 个研究点目标入组 90 人开始时间: 待定最近更新:

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
90

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
2 至 99(—)

入选标准

  • Substantial
  • 30 <= age <= 49 years
  • BMI >= 18.5 and <=25 kg/m2
  • In good health as assessed during screening (by questionnaire), and the
  • medical investigator*s professional judgment
  • Non-smoking
  • Substantial
  • 65 <= age <= 79 years
  • BMI 22.0 - 28.0 kg/m2
  • Generally healthy as assessed during screening (by questionnaire), and the
  • medical investigator*s professional judgment
  • Non-smoking
  • Procedural (both for adults and elderly):
  • Ability to follow Dutch verbal and written instructions
  • Signed informed consent
  • Willingness to give up blood donation during the entire study
  • Substantial
  • 3 <= age <= 6 years
  • Healthy BMI, cut-off points will be used as indicated by JGZ (BMI jongens en
  • meisjes | Voedingscentrum)
  • Generally healthy as assessed during screening (by parental anamnesis), and
  • the study physician*s professional judgment
  • Procedural:
  • Parents/caretakers having the ability to follow Dutch verbal and written
  • instructions
  • Signed informed consent

排除标准

  • Adults and elderly
  • Substantial
  • Chronic illness (e.g., diabetes mellitus, cardiac insufficiency, respiratory
  • insufficiency, cancer, chronic kidney or liver disease),
  • Acute infection in the past month
  • Gastrointestinal disorders (e.g., inflammatory bowel disease),
  • Acute gastroenteritis in the past 2 months
  • Any vaccination in the past month
  • Treatment with antibiotics within 2 months of the start of the study,
  • Regular use of laxative agents
  • Immunodeficiency disorder
  • Use of immunosuppressive drugs (e.g.cyclosporine, azathioprine, systemic
  • corticosteroids, antibodies)
  • Unexplained weight loss or weight gain of > 3 kg in the 3 months prior to
  • pre-study screening
  • Regular consumption of probiotics within 1 month before start of the study
  • Evidence of current excessive alcohol consumption (>4 consumptions/day or >20
  • consumptions/week) or drug (ab)use
  • Mental status that is incompatible with the proper conduct of the study
  • Procedural:
  • Not having a general practitioner, not allowing disclosure of participation
  • to the general practitioner or not allow to inform the general practitioner
  • about abnormal results. Participation in any clinical trial including
  • blood sampling and/or administration of substances starting 1 month prior
  • to study start and during the entire study.
  • Personnel of NIZO or Gnosis by Lesaffre, their partner and their first and
  • second degree relatives.
  • Substantial
  • Acute respiratory or gastrointestinal or chronic infections
  • Chronic systemic or metabolic diseases
  • Gastrointestinal disorders (e.g., inflammatory bowel disease),
  • Acute gastroenteritis in the past 2 months
  • Any vaccination in the past month
  • Treatment with antibiotics within 2 months of the start of the study,
  • Immunodeficiency disorder
  • Use of anti-inflammatory or immunosuppressive drugs (e.g.cyclosporine,
  • azathioprine, systemic corticosteroids, antibodies)
  • Regular use of laxative agents
  • Regular consumption of probiotic supplements within 1 month before start of
  • Procedural:
  • Parents or caretakers not having a general practitioner, not allowing
  • disclosure of participation to the general practitioner or not allowing to
  • inform the general practitioner about abnormal results.
  • Participation in any clinical trial starting 1 month prior to study
  • start and during the entire study.
  • Parents who are personnel of NIZO or Gnosis by Lesaffre, their partner and
  • their first and second degree relatives.

研究者

发起方
Gnosis by Lesaffre

相似试验